News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Neurocrine's strong Ingrezza growth, Crenessity momentum and expanding pipeline make it the stronger pick over Teva despite valuation risks.
Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.
Eli Lilly and Novo Nordisk both dominated GLP-1 headlines in Q2 2026, but one company raised guidance while the other announced layoffs, pipeline writedowns, and a dramatic price cut. The split screen tells a story that goes beyond which drug sells more.
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Healthcare stocks decreased late Monday afternoon, with the NYSE Healthcare Index and the State Stre
The obesity-drug leader is retreating despite growth that remains extraordinary by mega-cap standards.
On August 12, 2026, Eli Lilly and Company (NYSE:LLY) said that it filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide. It is an experimental obesity drug still in Phase 3 trials and not yet approved by regulators anywhere. Why This Matters Lilly is trying to shut down a […]
On August 13, 2026, Novo Nordisk A/S (NYSE:NVO) CEO Mike Doustdar told Reuters that investors are underestimating how much the obesity drug market will fragment as new treatments arrive. He pushed back on the idea that Novo and Eli Lilly and Company (NYSE:LLY) are locked in a zero-sum battle for the same shrinking pool of […]
Healthcare stocks were decreasing Monday afternoon, with the NYSE Healthcare Index and the State Str
Eli Lilly just crossed a $1 trillion market cap for the first time, and management is already pointing toward a milestone that would rewrite the drugmaker's history. Whether three converging pipeline catalysts can justify the valuation is the question every investor needs to answer now.
The share of every sales dollar Eli Lilly keeps as operating profit has roughly doubled against its own long-run record, and it is volume rather than price holding it there.
AMGN's strong growth drivers and promising pipeline support long-term growth, but patent losses, pricing pressure and valuation warrant caution.
Roche (USOTC:RHHBY) and Eli Lilly (NYSE:LLY) have secured clearance from the U. S.
Eli Lilly's weight-loss and diabetes pill goes on sale in UK pharmacies from Monday, giving patients an oral alternative to the injections that have dominated the market. Foundayo, also known as orforglipron, is available on private prescription after the Medicines and Healthcare products...
The Food and Drug Administration cleared a blood test for identifying Alzheimer’s disease symptoms, which was developed by Roche and Eli Lilly.
The once-daily pill was approved for patients with a body mass index of at least 30, or between 27 and 30 in the event of at least one weight-related health condition.
For $190 million up front and as much as $2.3 billion overall, the Swiss drugmaker is building its portfolio with a shot that aims to spur weight loss but spare muscle tissue.
Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial upside.
Eli Lilly and Co (NYSE:LLY) has launched its once-daily weight-management and diabetes pill Foundayo in UK pharmacies, offering patients an oral alternative to injectable GLP-1 treatments. Foundayo, also known as orforglipron, is available from Monday through private prescription after the...
By Andrew Silver SHANGHAI, Aug 24 (Reuters) - Weight-loss drugmakers, vying to tighten the belts of Chinese consumers, are promoting obesity awareness in metro stations, exercise studios and soccer
Could this little-known biotech be a hidden gem?
Eli Lilly just delivered one of the most staggering quarters in Big Pharma history, yet Wall Street is barely reacting. Three catalysts in the next 18 months could either push shares to levels few analysts dare to print or expose the cracks in a very expensive story.
Griffin's Q2 move is already paying off nicely.
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.
Veeva Systems recently secured Eli Lilly and Company’s commitment to deploy Veeva Vault CRM globally, while also announcing that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, to be succeeded by Dan Rizzo as EVP of Sales, Consulting, and Services. These developments arrive as Wall Street analysts anticipate higher upcoming quarterly earnings and revenue for Veeva, highlighting how large client wins and leadership transitions could shape the company’s...
Eli Lilly recently reported strong revenue growth driven by its Mounjaro and Zepbound obesity and diabetes drugs, raised full-year guidance, advanced its next-generation GLP-1 pipeline, and secured UK approval for Foundayo, its once-daily oral GLP-1 pill for weight management and type 2 diabetes. These developments, alongside vaccine research collaborations and ongoing legal action against unauthorized retatrutide sellers, highlight Lilly’s bid to extend its leadership across injectable,...
Mounjaro and Zepbound are widening Lilly's advantage while its next-generation pipeline adds fresh growth options.